Changing the Game in Atopic Dermatitis and Alopecia Areata: How Advanced Practice Providers and Emerging Agents Can Transform Care

This two-module activity provides targeted education to advanced practice providers (APPs) about the emerging therapies in moderate-to-severe atopic dermatitis (AD) and alopecia areata (AA). Delivered by a multidisciplinary team of providers including dermatologists, a nurse practitioner, a physician assistant, a pharmacist and a clinical psychologist, the discussion includes: a review of the limited available treatments for AD and AA, and the unmet need for more effective therapies with a good safety profile for long-term use; recognizing how the Janus kinase (JAK)-signal transducer activator of transcription pathways have an important role in the pathogenesis of AD and AA; interpretation of the latest clinical trial data of available and emerging oral JAK inhibitors currently under investigation; and exploring the unique role of advanced practice providers in delivering care and providing education for patients with AA and/or AD.

 

Target Audience

Dermatology and Allergy/Immunology-based physicians, pharmacists, nurse practitioners, physician assistants, nurses and other advanced practice providers

 

 

Learning Objectives

At the conclusion of this activity, participants will be able to (or better able to):

  1. Explore the changing paradigm of AA and AD disease presentation and treatment approaches.
  2. Evaluate risk factors and comorbidities of AA and AD as drivers of individualized treatment.
  3. Assess the burden of disease of both AA and AD, particularly with regard to patient quality of life and barriers to optimal treatment.
  4. Compare and contrast the latest clinical trial data among emerging oral agents in AA and/or AD and terms of therapeutic target, safety, efficacy, and tolerability.

 

Course summary
Available credit: 
  • 2.00 ACPE Pharmacy
  • 2.00 AMA PRA Category 1 Credit™
    Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Boston University School of Medicine designates this Enduring activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 ANCC
    Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
    • 2.00 ANCC Pharmacology
  • 2.00 Participation
Course opens: 
06/01/2022
Course expires: 
06/01/2023

 

 

FACULTY

Kristina Anderson, NP-C, DCNP, CANS
Certified Dermatology Nurse Practitioner
Certified Aesthetic Nurse Practitioner
Instructor of Dermatology
Boston University School of Medicine
Boston, Massachusetts

Ms. Anderson has no relevant financial relationships to disclose.

Lynne J. Goldberg, MD
Co-Course Director
Jag Bhawan Professor of Dermatology and Pathology and Laboratory Medicine
Boston University School of Medicine
Director, Hair Clinic
Boston Medical Center
Boston, Massachusetts

Dr. Goldberg has no relevant financial relationships to disclose.

Amanuel Kehasse, PharmD, PhD
Clinical Pharmacy Specialist in Rheumatology, Dermatology, and Interstitial Lung Disease
Boston Medical Center Health System
Boston, Massachusetts

Dr. Kehasse has no relevant financial relationships to disclose.

Peter Lio, MD
Co-Course Director
Assistant Professor of Clinical Dermatology and Pediatrics
Northwestern University, Feinberg School of Medicine
Director, Chicago Integrative Eczema Center
Founding Partner, Medical Dermatology Associates of Chicago
Chicago, IL

Dr. Lio, discloses he is on the advisory board for Boston Skin Science LLC, Janssen Pharmaceuticals Inc., Johnson and Johnson, DermTap Inc., DermVeda, Intraderm Pharmaceuticals, Regeneron, Sanofi US Services, Menlo Therapeutics, Syncere Skin Systems, gpower inc., UCB, Altus Labs, Dermavant Sciences, Micreos Human Health B.V., Arbonne, YobeeCare, Inc., Bodewell, ASLAN Pharmaceuticals, Almirall, MaskSense, Castle Biosciences, and Verrica Pharmaceuticals Inc.

He is a speaker for Abbvie, Incyte Corporation, Pierre Fabre Dermatologie, Regeneron, La Roche-Posay Laboratorie Pharmaceutique, Galderma USA, Eli Lilly and Company, Leo Pharma Inc., MyOR Diagnostics Ltd., ParentMD, and Pfizer Inc.

Dr. Lio is a consultant for Exeltis, Theraplex, Odeza LLC, L'Oreal USA Inc., Franklin BioScience, AbbVie, Kiniksa Pharmaceuticals, Ltd, Eli Lilly and Company, Unilever, and Dermira, Amyris, Inc., LEO Laboratories Ltd., Burt’s Bees, Kimberly Clark, Sonica LLC, MyOR Diagnostics Ltd., Sibel Health, Kaleido Biosciences, Lipidor, Skinfix Inc., and Concerto Biosciences.

Dr. Lio receives research support from Abbvie, AOBiome LLC, Foundation for Atopic Dermatitis, and Regeneron. He also receives royalties from ParentMD and Theraplex and is a stockholder for Modernizing Medicine, LearnHealth/LearnSkin, and Medable.

Lisa Lombard, MD
Licensed Clinical Psychologist
President, Board of Directors of the National Pediatric Hypnosis Training Institute
Research Assistant Professor
Northwestern University, Feinberg School of Medicine Center for Food Allergy & Asthma Research (CFAAR)
Department of Medical School Social Sciences
Chicago, IL

Dr. Lombard has no relevant financial relationships to disclose.

Aliza Stern, MD
Director of Didactic Education
Physician Assistant Program
Assistant Professor of Dermatology
Boston University School of Medicine
Boston, Massachusetts

Ms. Aliza Stern has no relevant financial relationships to disclose.

CME Project Manager: Michael Burk

 

CME Accreditation

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

ANCC Accreditation

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

CNE Contact Hours: 2.0, all of which is eligible for pharmacology credit

ACPE Accreditation

The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This is an application-based enduring educational activity. Pharmacists will receive 2.00 contact hours (0.20 CEUS) for the educational activity. No partial credit is available. Initial Release Date: May 31, 2022. Planned Expiration Date: May 31, 2023.

UNIVERSAL ACTIVITY NUMBER (UAN): 0060-9999-22-033-H01-P

 

Available Credit

  • 2.00 ACPE Pharmacy
  • 2.00 AMA PRA Category 1 Credit™
    Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Boston University School of Medicine designates this Enduring activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 ANCC
    Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
    • 2.00 ANCC Pharmacology
  • 2.00 Participation
Please login or register to take this course.